Michael Barbella, Managing Editor09.29.23
SamanTree Medical has a new leader.
The company has appointed former Miracor Medical chief executive and board member Olivier Delporte as CEO.
“We are excited for Olivier to join SamanTree Medical at this important time in the company’s growth as we focus on scaling commercial placements of the Histolog Scanner in Europe and planning the U.S. market expansion for 2024," SamanTree Medical Board Chairman Charles S. Carignan, M.D., said. "The Histolog Scanner has already been used in more than 2000 surgical procedures and the adoption is accelerating. With Olivier’s exceptional leadership experience and industry expertise, I am confident that he will play a pivotal role in driving our company’s growth and success.”
Delporte has more than 22 years of experience driving growth and innovation of fast-growing medtech companies across various therapeutic areas. He most recently led Miracor Medical, but before that was senior vice president of sales/marketing (international) for PneumRx Inc., according to his LinkedIn bio. Prior to PneumRx, Delporte was sales/marketing vice president (EMEA) at Tryton Medical. His medical device industry tenure also includes stints at Abbott Vascular (marketing manager for drug-eluting stents); Guidant (EMEAC product manager and sales associate, Endovascular); b2build (business development manager); and ISOVER Saint Gobain (sales manager). In addition, Delporte is a venture partner with SPRIG Equity and serves on the boards of both Intressa Vascular and Endo Tools Therapeutics.
“I am honored to work with a team that has already achieved so much. The shift towards digital and remote pathology is not just a prediction for the future—it’s our present reality," Delporte stated. "Our application of it in the operating room to provide answers to physicians in real time—in a fraction of the time of traditional frozen section analysis—puts SamanTree at the forefront of this wave. I am eager to accelerate our innovation and to explore how we can further harness this transformative technology to improve patient outcomes and hospitals’ workflows globally.”
Delporte’s expertise in multiple healthcare areas is a good match for the multidisciplinary applications of the Histolog Scanner, as recently highlighted by the multitude of published articles and presentations in various cancer surgery indications such as prostate, breast, brain and more broadly in pathology, according to SamanTree executives.
As the new CEO, Delporte will be responsible for overseeing the company’s strategic vision and driving global expansion. “I am thrilled to take part in the next phase of the company’s development and to foster strategic collaborations and partnerships. We will continue to push boundaries and seek investment that aligns with our vision and objectives,” he concluded.
SamanTree Medical has developed a breakthrough medical imaging modality that enables fast and high-resolution intra-operative assessment of resected tissue to improve cancer treatment. The Histolog Scanner (CE marked) allows for high resolution imaging of the surface of fresh tissue. The Histolog technology is based on ultra-fast confocal microscopy technology. By offering clinicians the chance for real-time assessment of fresh tissue, the clinician is one touch-on-the-screen away from visualizing cancerous cells immediately during surgery. It covers a broad range of surgical and diagnostic applications in oncology. The Histolog Scanner is commercialized in Europe and is an investigational device in the United States.
The company has appointed former Miracor Medical chief executive and board member Olivier Delporte as CEO.
“We are excited for Olivier to join SamanTree Medical at this important time in the company’s growth as we focus on scaling commercial placements of the Histolog Scanner in Europe and planning the U.S. market expansion for 2024," SamanTree Medical Board Chairman Charles S. Carignan, M.D., said. "The Histolog Scanner has already been used in more than 2000 surgical procedures and the adoption is accelerating. With Olivier’s exceptional leadership experience and industry expertise, I am confident that he will play a pivotal role in driving our company’s growth and success.”
Delporte has more than 22 years of experience driving growth and innovation of fast-growing medtech companies across various therapeutic areas. He most recently led Miracor Medical, but before that was senior vice president of sales/marketing (international) for PneumRx Inc., according to his LinkedIn bio. Prior to PneumRx, Delporte was sales/marketing vice president (EMEA) at Tryton Medical. His medical device industry tenure also includes stints at Abbott Vascular (marketing manager for drug-eluting stents); Guidant (EMEAC product manager and sales associate, Endovascular); b2build (business development manager); and ISOVER Saint Gobain (sales manager). In addition, Delporte is a venture partner with SPRIG Equity and serves on the boards of both Intressa Vascular and Endo Tools Therapeutics.
“I am honored to work with a team that has already achieved so much. The shift towards digital and remote pathology is not just a prediction for the future—it’s our present reality," Delporte stated. "Our application of it in the operating room to provide answers to physicians in real time—in a fraction of the time of traditional frozen section analysis—puts SamanTree at the forefront of this wave. I am eager to accelerate our innovation and to explore how we can further harness this transformative technology to improve patient outcomes and hospitals’ workflows globally.”
Delporte’s expertise in multiple healthcare areas is a good match for the multidisciplinary applications of the Histolog Scanner, as recently highlighted by the multitude of published articles and presentations in various cancer surgery indications such as prostate, breast, brain and more broadly in pathology, according to SamanTree executives.
As the new CEO, Delporte will be responsible for overseeing the company’s strategic vision and driving global expansion. “I am thrilled to take part in the next phase of the company’s development and to foster strategic collaborations and partnerships. We will continue to push boundaries and seek investment that aligns with our vision and objectives,” he concluded.
SamanTree Medical has developed a breakthrough medical imaging modality that enables fast and high-resolution intra-operative assessment of resected tissue to improve cancer treatment. The Histolog Scanner (CE marked) allows for high resolution imaging of the surface of fresh tissue. The Histolog technology is based on ultra-fast confocal microscopy technology. By offering clinicians the chance for real-time assessment of fresh tissue, the clinician is one touch-on-the-screen away from visualizing cancerous cells immediately during surgery. It covers a broad range of surgical and diagnostic applications in oncology. The Histolog Scanner is commercialized in Europe and is an investigational device in the United States.